company background image
REGN logo

Regeneron Pharmaceuticals NasdaqGS:REGN Voorraadrapport

Laatste prijs

US$843.60

Marktkapitalisatie

US$90.8b

7D

-9.2%

1Y

1.3%

Bijgewerkt

04 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

Regeneron Pharmaceuticals, Inc.

NasdaqGS:REGN Voorraadrapport

Marktkapitalisatie: US$90.8b

REGN Overzicht aandelen

Regeneron Pharmaceuticals, Inc. ontdekt, bedenkt, ontwikkelt, produceert en verkoopt wereldwijd geneesmiddelen voor de behandeling van verschillende ziekten.

Over het bedrijf

Beloningen

Trading at 60% below our estimate of its fair value
Earnings are forecast to grow 8.11% per year
Earnings grew by 16.6% over the past year
Analysts in good agreement that stock price will rise by 29.9%

Risicoanalyse

Significant insider selling over the past 3 months

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
WarrenAI
Based on Analyst Price Targets

Innovative Therapies And Critical Market Expansions Fuel Biotech Growth

Key Takeaways Dupixent's approval for COPD could notably increase Regeneron's respiratory disease market share by targeting a sizable untreated patient group. Expansion in ophthalmology and respiratory diseases, alongside a strong pipeline with over 35 clinical programs, supports Regeneron's potential for revenue growth and market diversification.
View narrative
US$1.13k
FV
25.6% undervalued intrinsic discount
8.10%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
5 days ago author updated this narrative

Regeneron Pharmaceuticals, Inc. Concurrenten

Gilead Sciences

NasdaqGS:GILD

US$111.4b

Amgen

NasdaqGS:AMGN

US$171.6b

Biogen

NasdaqGS:BIIB

US$25.3b

AbbVie

NYSE:ABBV

US$359.5b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Regeneron Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoersUS$843.60
52 Week HoogtepuntUS$1,211.20
52 Week LaagUS$783.57
Bèta0.12
11 maand verandering-16.71%
3 maanden verandering-20.88%
1 Jaar Verandering1.34%
33 jaar verandering35.46%
5 jaar verandering145.03%
Verandering sinds IPO3,893.37%

Recent nieuws en updates

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Nov 04

Recent updates

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Nov 04

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Sep 25

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Sep 09
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Regeneron Stock: Valuation Now Demands More Growth

Aug 26

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Aug 22
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aug 04
Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Aug 02

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Jul 11

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

May 21
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

May 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Apr 30
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Apr 10
Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Mar 26

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16
Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Feb 10

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Feb 02

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Jan 31
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Rendement voor aandeelhouders

REGNUS BiotechsUS Markt
7D-9.2%-0.7%-1.6%
1Y1.3%19.8%30.8%

Rendement versus industrie: REGN underperformed the US Biotechs industry which returned 19.8% over the past year.

Rendement versus markt: REGN underperformed the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is REGN's price volatile compared to industry and market?
REGN volatility
REGN Average Weekly Movement4.1%
Biotechs Industry Average Movement9.6%
Market Average Movement6.0%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stabiele aandelenkoers: REGN has not had significant price volatility in the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: REGN's weekly volatility (4%) has been stable over the past year.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
198814,165Leonard Schleiferwww.regeneron.com

Regeneron Pharmaceuticals, Inc. ontdekt, bedenkt, ontwikkelt, produceert en verkoopt wereldwijd geneesmiddelen voor de behandeling van verschillende ziekten. De producten van het bedrijf omvatten EYLEA-injectie voor de behandeling van leeftijdsgebonden maculadegeneratie en diabetisch macula-oedeem; bijziend choroïdale neovascularisatie; diabetische retinopathie; neovasculair glaucoom; en retinopathie van prematuriteit. Het levert ook Dupixent injectie voor de behandeling van atopische dermatitis en astma bij volwassenen en kinderen; Libtayo injectie voor de behandeling van metastatisch of lokaal gevorderd cutaan plaveiselcelcarcinoom; Praluent injectie voor heterozygote familiaire hypercholesterolemie of klinische atherosclerotische cardiovasculaire aandoeningen bij volwassenen; REGEN-COV voor covid-19; en Kevzara oplossing voor de behandeling van reumatoïde artritis bij volwassenen.

Regeneron Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Regeneron Pharmaceuticals zich tot de beurswaarde?
REGN fundamentele statistieken
MarktkapitalisatieUS$90.76b
Inkomsten(TTM)US$4.65b
Inkomsten(TTM)US$13.85b

19.5x

Koers/Winstverhouding

6.6x

P/S-verhouding

Is REGN overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
REGN resultatenrekening (TTM)
InkomstenUS$13.85b
Kosten van inkomstenUS$6.82b
BrutowinstUS$7.03b
Overige uitgavenUS$2.37b
InkomstenUS$4.65b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)43.26
Brutomarge50.75%
Nettowinstmarge33.61%
Schuld/Eigen Vermogen Verhouding6.8%

Hoe presteerde REGN op de lange termijn?

Bekijk historische prestaties en vergelijking